From gene editing to skin repair: a hope for people with dominant EB

Gene Editing Targets Dominant EB

Epidermolysis bullosa (EB) encompasses a group of rare genetic disorders that render skin and mucous membranes extremely fragile, leading to blisters and wounds from minor friction. Dominant forms, including dominant dystrophic EB and most epidermolysis bullosa simplex, arise from a single mutated gene copy that produces defective proteins—such as keratin in EBS or collagen VII in DDEB—disrupting skin integrity.

Unlike recessive subtypes, where both gene copies are faulty and therapies can add functional protein, dominant cases require silencing or correcting the harmful allele to avoid interference from the mutant protein. This distinction has delayed progress compared to recessive dystrophic EB, which benefited from approvals like beremagene geperpavec (Vyjuvek) in 2023 and prademagene zamikeracel (Zevaskyn) in 2025—topical and cell-based gene therapies that restore collagen VII and heal wounds.

Recent years have seen momentum build for dominant EB. Preclinical work on allele-specific CRISPR-Cas9 editing has demonstrated precise targeting of mutant alleles in patient-derived cells, restoring skin strength in models. Advances in prime editing and other tools further enhance precision for monogenic skin disorders. In 2025-2026, research portfolios from groups like EB Research Partnership highlight curative projects expanding beyond symptoms, with gene editing viewed as the most promising path to a true cure.

The stakes remain high. Dominant EB patients endure chronic pain, repeated infections, nutritional challenges from oral involvement, and elevated squamous cell carcinoma risk in dystrophic forms. Without intervention, life expectancy shortens in severe cases, and quality of life erodes under constant wound care. Costs of managing symptoms run into hundreds of thousands annually per patient, while inaction perpetuates suffering across generations given 50% inheritance odds.

Tensions persist: off-target editing risks, delivery challenges to skin stem cells, and immune responses to corrected proteins in naive patients. Yet the field benefits from spillover from broader CRISPR applications and regulatory pathways opened by recent EB approvals, creating a rare-disease inflection point where dominant forms may soon follow recessive ones toward clinical translation.